NICOLE CHRISMAN: Open Payments
NPI 1669198859 · PHOENIX, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,067 in 42 payments from 11 companies in 2025. Trend: 2023 $1,165 · 2024 $2,554 · 2025 $2,067
Food & beverage: $2,067
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 19 | $1,141 |
| Gilead Sciences, Inc. | 4 | $351 |
| ABBVIE INC. | 7 | $216 |
| Ipsen Biopharmaceuticals, Inc | 1 | $122 |
| AstraZeneca Pharmaceuticals LP | 2 | $70 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $55 |
| Mirum Pharmaceuticals, Inc. | 2 | $34 |
| Novo Nordisk Inc | 1 | $26 |
| Intercept Pharmaceuticals, Inc. | 1 | $18 |
| ORPHALAN INC | 1 | $17 |
Products named: REZDIFFRA, MAVYRET, Vemlidy, IQIRVO, Trodelvy, Livdelzi, XIFAXAN, BEVESPI AEROSPHERE.
Industry payments across AZ — which companies pay providers there.
